Contineum Therapeutics (CTNM) Assets Average (2024 - 2026)

Contineum Therapeutics' Assets Average history runs 3 years deep, the most recent figure standing at $269.0 million for Q1 2026.

• On a quarterly basis, Assets Average rose 30.86% year-over-year to $269.0 million in Q1 2026; TTM through Mar 2026 was $269.0 million, a 30.86% increase from a year earlier, with the FY2025 full-year figure at $244.7 million, up 42.61% from the prior year.
• Assets Average climbed to $269.0 million in Q1 2026 per CTNM's latest filing, from $233.7 million in the prior quarter.
• Across five years, Assets Average topped out at $269.0 million in Q1 2026 and bottomed at $127.0 million in Q1 2024.
• The 3-year median for Assets Average is $205.6 million (2025), against an average of $202.0 million.
• Biggest YoY gain for Assets Average was 61.89% in 2025; the steepest drop was 14.55% in 2025.
• Year by year, Assets Average stood at $214.4 million in 2024, then grew by 9.0% to $233.7 million in 2025, then gained by 15.08% to $269.0 million in 2026.
• Per Business Quant, the three latest CTNM Assets Average figures stand at $269.0 million (Q1 2026), $233.7 million (Q4 2025), and $186.9 million (Q3 2025).